Nuvectis Pharma Inc., a clinical stage biopharmaceutical company, has announced the initiation of the Phase 1b program for its investigational drug NXP900. The program aims to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors with specific genetic alterations and in combination with EGFR and ALK inhibitors in NSCLC patients who have developed resistance to these treatments. The announcement follows the successful completion of previous studies, including a dose escalation study in patients with advanced solid tumors and a clinical drug-drug interaction study in healthy volunteers. The company has scheduled a conference call for August 12, 2025, to discuss the details of the Phase 1b program and the market opportunity for NXP900. Results from this program are anticipated in the future, as the single agent component has just begun and the combination component is expected to start later this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.